ERCC1在晚期非小细胞肺癌中的表达及临床意义  

Study on the Expression and Clinical Significance of ERCCl in Advanced Non-small Cell Lung Cancer

作　　者：伍建蓉[1] 郑玲[1] 李佽[2] 刘都礼[2] 白娟[1] 谷焰[1] 

机构地区：[1]成都大学附属医院肿瘤科,成都610041 [2]成都大学附属医院病理科,成都610081

出　　处：《肿瘤预防与治疗》2011年第5期225-228,共4页Journal of Cancer Control And Treatment

摘　　要：目的：探讨核苷酸切除修复交叉互补基因1（ERCC1）在晚期非小细胞肺癌中的表达及其临床意义。方法：采用免疫组化S-P法检测78例Ⅲ期、Ⅳ期非小细胞肺癌患者中核苷酸切除修复交叉互补基因1（ERCC1）的表达情况。所有患者均以铂类为基础的化疗方案化疗。将患者化疗疗效和生存资料与ERCC1的表达进行比较。结果：78例患者ERCC1的阳性表达率为47．4.4％（37／78），ERCC1表达与患者性别、年龄、病理类型（鳞癌、腺癌）及临床分期无关；ERCC1阴性组化疗临床受益率是73．17％（30／41），ERCC1阳性组为51．35％（19／37），两组比较差异有统计学意义（x^2=3．9643，P=0．0465）。ERCC1阳性组生存期为（21．1852±22．1134）月，ERCC1阴性组生存期为（12．375±10．0827）月，两组比较差异无统计学意义（P=0．0879）。结论：ERCC1的表达与晚期非小细胞肺癌患者铂类药物化疗临床受益相关，检测ERCC1的表达对化疗药物的选择有一定指导意义。Objective： To explore the expression and clinical significance of ERCC1 in advanced non-small cell lung cancer （NSCLC）. Methods： The expression of ERCC1 was examined by immuno-histochemical technique in 78 patients with advanced non- small cell lung cancer. All patients were treated with platinum-based chemotherapy. The response rates and survival data were collected and analyzed. Results： The expression of ERCC1 was 47.44% among 78 cases, and there was no correlation between the expression of ERCC1 and patient age, clinical stage, pathological type and gender; the response rate（ CR ＋ PR ＋ NC） in ERCC1 positive group was obviously lower than that in ERCC1 negative group （51.35% vs 73.17%, P =0. 0465）. However,the survival data of the ERCC1 negative group was lower than that of the ERCC1 positive group （P = 0. 0879）. Conclusion： The expression of ERCC1 is Correlated with platinum-based chemotherapy sensitivity in advanced non-small cell lung cancer. ERCC1 gene detection may help to guide drug choosing for chemotherapy.

关 键 词：非小细胞肺癌 基因表达 ERCC1 免疫组织化学 

分 类 号：R734.2[医药卫生—肿瘤]